Delix Therapeutics (Series A+)
Funding Details
Awarder
Gaingels
Date Award
May 24, 2024
Vertical
Healthcare and Biotech
Valuation
$250,000,000
Company Info
Founders
Mark Rus
Market
Healthcare & Wellness
Coinvestors
ARTIS Ventures
Company Description

Based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens, Delix is building a company to find solutions for CNS-related diseases.. Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.